Recursion Pharmaceuticals, INC Form 4 insider transactions

Recursion Pharmaceuticals CEO Christopher Gibson disposed of 40,390 Class A Common Stock shares for tax withholding purposes.

A Recursion Pharmaceuticals executive disclosed pre-planned sales of Class A Common Stock to cover tax obligations related to restricted stock unit vesting.

Recursion Pharmaceuticals CEO Christopher Gibson reported the sale of over 600,000 Class A shares at $5.28 each, alongside conversions and a gift, all under a pre-arranged 10b5-1 trading plan.

Dean Y. Li, a Director at Recursion Pharmaceuticals, Inc. (RXRX), acquired 1,949 shares of Class A Common Stock as part of the company's Outside Director Compensation Policy.

Recursion Pharmaceuticals, Inc. Director Zavain Dar acquired 2,924 shares of Class A Common Stock on July 1, 2025, as part of the company's Outside Director Compensation Policy.

Blake Borgeson, a Director at Recursion Pharmaceuticals, Inc., was granted 22,016 restricted stock units and options to purchase 44,031 shares of Class A Common Stock as part of the company's Outside Director Compensation Policy.

Recursion Pharmaceuticals, Inc. Director Franziska Michor was granted 22,016 restricted stock units and 44,031 stock options, valued at approximately $225,000 based on the option exercise price, as part of the company's outside director compensation policy.

Robert Hershberg, a Director at Recursion Pharmaceuticals, Inc., was granted 22,016 restricted stock units and options to purchase 44,031 shares of Class A Common Stock as part of his compensation.

Recursion Pharmaceuticals, Inc. Director Zavain Dar was granted 22,016 restricted stock units and options to purchase 44,031 shares of Class A Common Stock as part of the company's compensation policy.

Namandje Bumpus, a Director at Recursion Pharmaceuticals, Inc. (RXRX), was granted 11,008 restricted stock units and options to purchase 22,016 shares of Class A Common Stock as part of her compensation.

Dean Y. Li, a Director at Recursion Pharmaceuticals, Inc., reported the acquisition of 22,016 restricted stock units and 44,031 stock options on June 18, 2025, as part of the company's compensation policy.

Elaine Sun, a Director at Recursion Pharmaceuticals, Inc. (RXRX), was granted 11,008 restricted stock units and options to purchase 22,016 shares of Class A Common Stock as part of the company's Outside Director Compensation Policy.

Recursion Pharmaceuticals, Inc. Chief Financial Officer Ben R. Taylor reported the disposition of 7,057 Class A Common Stock shares to cover tax withholding obligations related to restricted stock unit vesting.

Najat Khan, Chief R&D Commercial Officer at Recursion Pharmaceuticals, disposed of shares to cover tax withholding obligations related to the settlement of restricted stock units.

Ben R. Taylor, CFO of Recursion Pharmaceuticals, filed a Form 4 disclosing changes in his beneficial ownership of company stock due to tax withholding related to restricted stock units.

CEO Christopher Gibson reports the withholding of 36,197 Class A Common Stock shares by Recursion Pharmaceuticals to cover tax obligations related to restricted stock units.

Ben R. Taylor, CFO of Recursion Pharmaceuticals, reports a transaction involving the withholding of shares to cover tax obligations related to restricted stock units.

Director Dean Y. Li reports the acquisition of shares in Recursion Pharmaceuticals, along with adjustments to beneficial ownership.

Director Zavain Dar acquired 2,745 shares of Recursion Pharmaceuticals' Class A Common Stock on April 1, 2025, under the company's Outside Director Compensation Policy.

Christopher Gibson, CEO of Recursion Pharmaceuticals, sold 138,574 shares of Class A Common Stock at $6.04 per share on March 27, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Ben R. Taylor, CFO of Recursion Pharmaceuticals, reports a transaction involving the withholding of shares to cover tax obligations related to restricted stock units.

Director Namandje Bumpus receives stock and option grants from Recursion Pharmaceuticals under the company's Outside Director Compensation Policy.

Director Sun Elaine D reports acquisition of restricted stock units and stock options in Recursion Pharmaceuticals, granted under the company's Outside Director Compensation Policy.

Christopher Gibson, CEO of Recursion Pharmaceuticals, reported the conversion and sale of Class A Common Stock on March 5th and 6th, 2025, according to a Form 4 filing.

Christopher Gibson, CEO of Recursion Pharmaceuticals, reports a transaction involving the withholding of shares to cover tax obligations and updates on derivative securities holdings.

Ben R. Taylor, CFO of Recursion Pharmaceuticals, disposed of 10,879 shares to cover tax obligations related to restricted stock units on February 18, 2025.

Christopher Gibson, CEO of Recursion Pharmaceuticals, reports the conversion and sale of Class A Common Stock, along with holdings in derivative securities.

Ben R. Taylor, CFO of Recursion Pharmaceuticals, reports acquisition and disposal of Class A Common Stock and stock options.

Najat Khan, Chief R&D Commercial Officer at Recursion Pharmaceuticals, reports acquisition and disposal of Class A Common Stock and stock options.

Christopher Gibson, CEO of Recursion Pharmaceuticals, filed a Form 4 detailing transactions involving Class A Common Stock and stock options.